实时全球研报
INDIA FIRST TO MARKET
研报英文原文证据摘录
INDIA FIRST TO MARKET
Asia Pacific Equity Research
India First to Market 30 July 2026
Top Stories
India Pharma (Bansi Desai, CFA)
US IQVIA Pulse – Base business flattish sequentially
This report tracks US trends and performance for key Indian pharma players using IQVIA data. It also includes our US
comparison matrix, notable product-level shifts, and JPM US revenue estimates across in-market and pipeline products.
Asian Paints Limited (Latika Chopra, CFA) (APNT IN, OW)
Strong Q1 sets the canvas, watch Q2 volumes & crude
APNT’s Q1 operational performance was strong, with consolidated revenue growth accelerating to ~18%. Decorative volumes
were up +9%, aided by healthy underlying demand through the quarter and continued execution on its strategic levers—
innovation, premiumization, and a more regionalized go-to-market approach. On the earnings call ( First Take ), management
shared a confident narrative of sustaining 8–10% decorative volume growth in FY27, supported by steady demand and an
expected uplift from the festive season, even as trends in Tier-1/Tier-2 cities appeared relatively modest. B2B/Industrial
demand remained strong and rural continued to outperform urban growth. Further pricing actions (wt avg: 6-7%; mix: 3%)
across the portfolio are likely to keep the growth trajectory intact. Value–volume gap turned positive (after multiple quarters),
and management expects it to remain so until further price corrections flow through. Competitive intensity continues to remain
elevated, but APNT gained shares (vs smaller players) on the back of stronger supply-chain reliability and sourcing capabilities
during volatile periods. Despite the inflationary COGS (~25% in Q1), EBITDA margin (20.6%) exceeded the guided range of
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文，不做批量翻译；登录后在阅读器切换中文时才按需翻译。
打开研报阅读器